Opsynvi, Macitentan Plus Tadalafil, Approved in Canada for PAH

Opsynvi, Macitentan Plus Tadalafil, Approved in Canada for PAH

310150

Opsynvi, Macitentan Plus Tadalafil, Approved in Canada for PAH

Opsynvi, a fixed-dose oral combination of macitentan and tadalafil, was approved by Health Canada for the long-term treatment of pulmonary arterial hypertension (PAH). It is for use by patients on stable doses of its two active compounds: macitentan (sold as Opsumit) at 10 mg and tadalafil (sold as Adcirca) at 40 mg. Marketed by Janssen, Opsynvi was approved as a more convenient, once-daily treatment to help ease symptoms in people with World Health Organization (WHO) functional class II or III PAH that is idiopathic…

You must be logged in to read/download the full post.